ClinicalTrials.Veeva
Menu

Find clinical trials for Heart Disease in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Heart Diseases
Coronary Artery Disease
Cardiovascular Diseases
Heart Failure
Myocardial Ischemia
Coronary Disease
Hypertension

Heart Disease trials near Rochester, MN, USA:

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study ...

Active, not recruiting
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Drug: NNC6019-0001
Drug: Placebo (NNC6019-0001)

Phase 2

Novo Nordisk
Novo Nordisk

Rochester, Minnesota, United States and 32 other locations

To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic valve....

Active, not recruiting
Mitral Valve Disease
Heart Failure
Device: Edwards SAPIEN 3 transcatheter valve, Model 9600TFX
Edwards Lifesciences
Edwards Lifesciences

Rochester, Minnesota, United States and 11 other locations

Locations recently updated

This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe ...

Enrolling
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Drug: NNC6019-0001

Phase 2

Novo Nordisk
Novo Nordisk

Rochester, Minnesota, United States and 30 other locations

The purpose of this study is to further evaluate the safety and effectiveness of the Harmony™ TPV system. The Pivotal/CAS phases of the study have tr...

Active, not recruiting
Congenital Heart Disease
Tetrology of Fallot
Device: Harmony TPV System
Medtronic
Medtronic

Rochester, Minnesota, United States and 11 other locations

in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated tha...

Enrolling
Heart Attack
Cardiovascular Diseases
Device: AliveCor 12-lead ECG
AliveCor

Rochester, Minnesota, United States and 1 other location

This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failin...

Enrolling
Aortic Stenosis, Severe
Aortic Stenosis
Device: Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Edwards Lifesciences
Edwards Lifesciences

Rochester, Minnesota, United States and 50 other locations

To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) in patients with severe, calcific aortic s...

Active, not recruiting
Aortic Stenosis
Procedure: SAVR
Device: SAPIEN 3 THV
Edwards Lifesciences
Edwards Lifesciences

Rochester, Minnesota, United States and 76 other locations

This study will evaluate the safety and effectiveness of the Edwards SAPIEN 3/SAPIEN 3 Ultra Transcatheter Heart Valve (THV) compared with c...

Active, not recruiting
Heart Diseases
Aortic Stenosis, Severe
Device: Edwards SAPIEN 3 / SAPIEN 3 Ultra THV
Edwards Lifesciences
Edwards Lifesciences

Rochester, Minnesota, United States and 76 other locations

The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with...

Enrolling
Persistent Atrial Fibrillation
Device: FARAPULSE™ Pulsed Field Ablation (PFA) System
Drug: Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Boston Scientific
Boston Scientific

Rochester, Minnesota, United States and 72 other locations

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Olpasiran
Drug: Placebo

Phase 3

Amgen
Amgen

Rochester, Minnesota, United States and 736 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems